Search | IOVS | ARVO Journals

Showing 1 – 20 of 100

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2023

Comparison of a Deep Learning based OCT image segmentation algorithm to manual segmentation by a traditional reading center for patients with wet AMD

Sparkle Russell-Puleri; Sara L Gale; Dzmitry A. Kaliukhovich; Joseph Blair; Romina Lasagni; Sandro De Zanet; Najat Khan; Daniel L Chao; Tripthi Kamath; Natasa Jovic; Anthony Pepio; H. Nida Sen

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):316.

ARVO Annual Meeting Abstract June 2022

Development of a CRISPR dCas9-KRAB based strategy for treatment for dominant retinal degenerative blindness

Erin R Burnight; Luke A Wiley; Malavika K. Adur; Dalyz Ochoa; Emily E. Kaalberg; Mallory Lang; Jeremy M. Hoffman; Chunhua Jiao; Stephen R Russell; Ian Han; Elliott H Sohn; Jason W. Ross; Robert F Mullins; Edwin M Stone; Budd A. Tucker

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1775 – F0324.

ARVO Annual Meeting Abstract June 2022

Efficacy and safety of sepofarsen, an intravitreal RNA antisense oligonucleotide, for the treatment of CEP290 -associated Leber congenital amaurosis (LCA10): a randomized, double-masked, sham-controlled, Phase 3 study (ILLUMINATE)

Bart Peter Leroy; Katarina Stingl; Isabelle S Audo; Camiel J F Boon; Fernanda Belga O Porto; Michel Michaelides; Helene Dollfus; L. Ingeborgh van den Born; Lyubomyr M Lytvynchuk; Francesca Simonelli; Juliana M F Sallum; Robert K Koenekoop; Elise Heon; Stephen R Russell; Michael Schwartz; Aniz Girach

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4536 – F0323.

ARVO Annual Meeting Abstract June 2022

Long-term safety and efficacy of sepofarsen in a Ph1b/2 INSIGHT extension trial in CEP290 -associated Leber congenital amaurosis (LCA10)

Stephen R Russell; Arlene V Drack; Artur V Cideciyan; Samuel G. Jacobson; Bart P Leroy; Caroline Van Cauwenbergh; Michael Schwartz; Aniz Girach

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):453.

ARVO Annual Meeting Abstract June 2021

Five-Year Post-Injection Results of the Phase 3 Trial of Voretigene Neparvovec-rzyl in Biallelic RPE65 Mutation-Associated Inherited Retinal Disease

Jean Bennett; Stephen R Russell; Katherine A High; Arlene V Drack; Zi-Fan Yu; Daniel C Chung; Kathy Reape; Albert M Maguire

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3540.

ARVO Annual Meeting Abstract June 2021

Safety and efficacy of sepofarsen in the second treated eye in a Ph1b/2 extension trial in Leber Congenital Amaurosis type 10 (LCA10)

Stephen R Russell; Arlene V Drack; Artur V Cideciyan; Samuel G Jacobson; Bart Leroy; Allen Ho; Caroline Van Cauwenbergh; Arun kumar Krishnan; Wilhelmina R. den Hollender; Adriana Hollestein-Havelaar; Mike Schwartz; Aniz Girach

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3317.

Articles May 2021

Feasibility Study of a Multimodal, Cloud-Based, Diabetic Retinal Screening Program in a Workplace Environment

PDF

Jeffrey R. Willis; Ferhina S. Ali; Braelyn Argente; Amitha Domalpally; Jacqueline Gannon; Simon S. Gao; Shagun Grover; Purti Kanodia; Sparkle Russell-Puleri; Diana Sun; Cory Thrasher; Costas Tsougarakis; J. Jill Hopkins
TAGS: diabetes mellitus, feasibility studies, retinal screening, workplace, vision, self-report, transfer technique
Trans. Vis. Sci. Tech.. 2021; 10(6):20. https://doi.org/10.1167/tvst.10.6.20

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2020

Inherited Retinal Disease (IRD): Online medical education can significantly improve knowledge and confidence for detection in general ophthalmology practice and referral for gene therapy assessment

Siggi Trier; Deborah Middleton; Peter Schoonheim; Jason Comander; Helene Dollfus; Stephen R Russell; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3020.

ARVO Annual Meeting Abstract June 2020

Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 gene

Stephen R Russell; Arlene V Drack; Artur V Cideciyan; Samuel G Jacobson; Bart Peter Leroy; Wanda L. Pfeifer; Alina V. Dumitrescu; Alexandra V. Garafolo; Allen C. Ho; Caroline Van Cauwenbergh; Julie De Zaeytijd; Aniz Girach; Wil den Hollander; Mike Schwartz; David M. Rodman

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):866.

ARVO Annual Meeting Abstract June 2020

Subretinal implantation of biodegradable photoreceptor cell delivery scaffolds: surgical tools, procedures and outcomes

Elliott H Sohn; Razek Coussa; Ian C Han; Chunhua Jiao; Jessica Thompson; Kristan Worthington; Robert F Mullins; Edwin M Stone; Budd Tucker; Stephen R Russell

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):867.

ARVO Annual Meeting Abstract July 2019

CEP290 -associated LCA due to a photoreceptor cilium defect treated with an intravitreal antisense oligonucleotide results in improved vision

Artur V Cideciyan; Samuel G Jacobson; Arlene V Drack; Allen C Ho; Alexandra Garafalo; Alejandro J Roman; Mike Schwartz; Patricia Biasutto; Wilma de Wit; Michael E Cheetham; Peter S Adamson; David Rodman; Julie De Zaeytijd; Caroline Van Cauwenbergh; Bart P Leroy; Stephen R Russell

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1834.

ARVO Annual Meeting Abstract July 2019

Progressive Neurodegeneration in Macular Telangiectasia Type 2 (MacTel)

Alec Lee Amram; S. Scott whitmore; Christine Clavell; Lance Lyons; Alexander Michael Rusakevich; Ian Han; James C Folk; H Culver Boldt; Karen Gehrs; Edwin M Stone; Stephen R Russell; Kyungmoo Lee; Michael David Abramoff; Charles Clifton Wykoff; Elliott H Sohn

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2570.

ARVO Annual Meeting Abstract July 2019

Navigation Assistance From the Low-Vision Enhancement Optoelectronic (LEO) Belt

Nicole Tatro; Ian Andrews; Terry Braun; Stephen R Russell

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4019.

ARVO Annual Meeting Abstract July 2019

Visual Function Questionnaire Responses in the Voretigene Neparvovec Phase 3 Trial

Stephen R Russell; Albert M. Maguire; Jean Bennett; Paulo Falabella; Elliott H Sohn; Vinit B Mahajan; Daniel C Chung; Kathleen Z Reape; Katherine A High

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4968.

Articles November 2018

Correlation of Optical Coherence Tomography and Retinal Histology in Normal and Pro23His Retinal Degeneration Pig

PDF

Justine Cheng; Elliott H. Sohn; Chunhua Jiao; Kelsey L. Adler; Emily E. Kaalberg; Stephen R. Russell; Robert F. Mullins; Edwin M. Stone; Budd A. Tucker; Ian C. Han
TAGS: histology, optical coherence tomography, retinal degeneration, eye, diagnostic imaging
Trans. Vis. Sci. Tech.. 2018; 7(6):18. https://doi.org/10.1167/tvst.7.6.18

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2018

Three-year update for the phase 3 voretigene neparvovec study in biallelic RPE65 mutation–associated inherited retinal disease

Stephen R Russell; Jean Bennett; Jennifer Wellman; Daniel C Chung; Katherine High; Zi-Fan Yu; Amy Tillman; Albert M Maguire

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3900.

ARVO Annual Meeting Abstract June 2017

Does fluorescein angiography add value in the management of suspected choroidal neovascularization?

Prashant Parekh; James C Folk; Stephen R Russell; Elliott Sohn; Michael David Abramoff

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1857.

ARVO Annual Meeting Abstract June 2017

Compatibility of a biodegradable retinal cell graft for the treatment of retinal degenerative blindness

Elliott Sohn; Kristan Sorenson Worthington; Chunhua Jiao; Emily E. Kaalberg; Stephen R Russell; Katherine N. Gibson-Corley; Robert F Mullins; Edwin M Stone; Budd Tucker

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4585.

ARVO Annual Meeting Abstract June 2017

Year 2 results for a phase 3 trial of voretigene neparvovec in biallelic RPE65 -mediated inherited retinal disease

Stephen R Russell; Jean Bennett; Jennifer A. Wellman; Daniel C Chung; Katherine A High; Zi-Fan Yu; Amy Tillman; Albert M Maguire

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4122.

ARVO Annual Meeting Abstract June 2017

Correlation of multi-luminance mobility testing with visual function tests in a phase 3 trial of voretigene neparvovec for biallelic RPE65 -mediated inherited retinal disease

Daniel C Chung; Stephen R Russell; Jean Bennett; Albert M Maguire; Jennifer A. Wellman; Zi-Fan Yu; Amy Tillman; Katherine A High

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3292.

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Comparison of a Deep Learning based OCT image segmentation algorithm to manual segmentation by a traditional reading center for patients with wet AMD

Development of a CRISPR dCas9-KRAB based strategy for treatment for dominant retinal degenerative blindness

Efficacy and safety of sepofarsen, an intravitreal RNA antisense oligonucleotide, for the treatment of CEP290 -associated Leber congenital amaurosis (LCA10): a randomized, double-masked, sham-controlled, Phase 3 study (ILLUMINATE)

Long-term safety and efficacy of sepofarsen in a Ph1b/2 INSIGHT extension trial in CEP290 -associated Leber congenital amaurosis (LCA10)

Five-Year Post-Injection Results of the Phase 3 Trial of Voretigene Neparvovec-rzyl in Biallelic RPE65 Mutation-Associated Inherited Retinal Disease

Safety and efficacy of sepofarsen in the second treated eye in a Ph1b/2 extension trial in Leber Congenital Amaurosis type 10 (LCA10)

Feasibility Study of a Multimodal, Cloud-Based, Diabetic Retinal Screening Program in a Workplace Environment

Inherited Retinal Disease (IRD): Online medical education can significantly improve knowledge and confidence for detection in general ophthalmology practice and referral for gene therapy assessment

Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 gene

Subretinal implantation of biodegradable photoreceptor cell delivery scaffolds: surgical tools, procedures and outcomes

CEP290 -associated LCA due to a photoreceptor cilium defect treated with an intravitreal antisense oligonucleotide results in improved vision

Progressive Neurodegeneration in Macular Telangiectasia Type 2 (MacTel)

Navigation Assistance From the Low-Vision Enhancement Optoelectronic (LEO) Belt

Visual Function Questionnaire Responses in the Voretigene Neparvovec Phase 3 Trial

Correlation of Optical Coherence Tomography and Retinal Histology in Normal and Pro23His Retinal Degeneration Pig

Three-year update for the phase 3 voretigene neparvovec study in biallelic RPE65 mutation–associated inherited retinal disease

Does fluorescein angiography add value in the management of suspected choroidal neovascularization?

Compatibility of a biodegradable retinal cell graft for the treatment of retinal degenerative blindness

Year 2 results for a phase 3 trial of voretigene neparvovec in biallelic RPE65 -mediated inherited retinal disease

Correlation of multi-luminance mobility testing with visual function tests in a phase 3 trial of voretigene neparvovec for biallelic RPE65 -mediated inherited retinal disease

To View More...

You must be signed into an individual account to use this feature.